Estradiol benzoate/progesterone
| Combination of | |
|---|---|
| Estradiol benzoate | Estrogen | 
| Progesterone | Progestogen | 
| Clinical data | |
| Trade names | Clinomin Forte, Duogynon, Lutrogen, Sistocyclin, Vermagest, others | 
| Other names | EB/P4 | 
| Routes of administration | Intramuscular injection (oil solution, aqueous suspension) | 
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
Estradiol benzoate/progesterone (EB/P4), sold under the brand names Duogynon and Sistocyclin among others, is a combination medication of estradiol benzoate (EB), an estrogen, and progesterone (P4), a progestogen. It has been formulated both as short-acting oil solutions and long-acting microcrystalline aqueous suspensions and is given by injection into muscle either once or continuously at regular intervals.
EB/P4 was one of the first combined estrogen and progestogen medications to be introduced for medical use. It was first marketed in Germany as an oil solution in 1950. Microcrystalline EB/P4 in aqueous suspension was developed and marketed under the brand name Sistocyclin several years later. EB/P4 was eventually superseded by longer-acting parenteral estrogen–progestogen combinations as well as by oral estrogen–progestogen combinations.